The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer
In HR positive advanced breast cancer patients treated with first-line CDK4/6 inhibitors, lower BMI is associated with poorer prognosis.
Authors
- Yiwen Ma (ORCID: https://orcid.org/0009-0003-6289-1021)
- Tao Sun (ORCID: https://orcid.org/0000-0002-8962-2193)
- Xiaorui Li (ORCID: https://orcid.org/0009-0007-5268-0166)
- Yujun Jiang (ORCID: https://orcid.org/0000-0002-2857-2137)
- Sijia Wu (ORCID: https://orcid.org/0009-0003-8569-328X)
- Liping Xiao (ORCID: https://orcid.org/0000-0002-9763-3001)
- Ying Wang (ORCID: https://orcid.org/0000-0001-6632-5754)
Institutions
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1080/07853890.2025.2597068
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56